Conduit Pharmaceuticals Inc. (NASDAQ:CDT) Short Interest Update

Conduit Pharmaceuticals Inc. (NASDAQ:CDT) was the target of a significant drop in short interest in November. As of November 15th, there was short interest totalling 2,360,000 shares, a drop of 33.9% from the October 31st total of 3,570,000 shares. Based on an average daily volume of 22,220,000 shares, the short-interest ratio is currently 0.1 days.

Conduit Pharmaceuticals Trading Up 8.0 %

Shares of NASDAQ:CDT traded up $0.01 during trading on Friday, reaching $0.11. 9,347,975 shares of the stock traded hands, compared to its average volume of 37,767,360. The stock has a 50-day moving average of $0.11 and a two-hundred day moving average of $0.68. Conduit Pharmaceuticals has a 52-week low of $0.08 and a 52-week high of $7.83.

Insider Buying and Selling at Conduit Pharmaceuticals

In other news, major shareholder Ltd Nirland sold 333,177 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $0.10, for a total transaction of $33,317.70. Following the sale, the insider now owns 9,900,000 shares in the company, valued at $990,000. This represents a 3.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders sold 3,658,000 shares of company stock valued at $386,136. Corporate insiders own 34.74% of the company’s stock.

About Conduit Pharmaceuticals

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.